Sort   by:  
 Page size 
UnknownTreatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Not available
S-EPMC4289722 | biostudies-literature
UnknownTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Not available
S-EPMC3413275 | biostudies-literature
UnknownKi67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Not available
S-EPMC5455353 | biostudies-literature
ProteomicsMass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancer

Filip Mundt, Sandeep Rajput, Shunqiang Li, Kelly Ruggles, Arshag D. Mooradian, Philipp Mertins, Michael A. Gillette, Karsten Krug, et al., Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990.

Activation of phosphoinositide 3-kinase (PI3K) signaling is frequently obs...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2018-10-19 | MSV000083050 | MassIVE
TranscriptomicsTBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer
Abstract Background. Epidermal growth factor receptor (EGFR) is a targetable molecule in basal-like breast cancer, which comprises most “triple negative” breast cancer (TNBC), the only breast cancer subtype without established targeted therapy. Methods. In this randomized phase II trial, metastatic ...
ORGANISM(S): Homo sapiens 
2012-07-13 | E-GEOD-23428 | biostudies-arrayexpress
Sort   by:  
 Page size